$14.000
+0.020 (+0.14%)收盘时
VTYX 资讯
VTYX 事件
Significant Increases in Borrow Rates for Liquid Options
Latest data shows the largest indicative borrow rate increases among liquid option names include: PowerShares DB US Dollar Index Bullish Fund (UUP) 5.40% +1.09, VisionWave Holdings Inc (VWAV) 102.71% +1.00, T-REX 2X Long BMNR Daily Target ETF (BMNU) 30.17% +0.94, Star Bulk Carriers (SBLK) 2.23% +0.94, AXS TSLA Bear Daily ETF (TSLQ) 5.00% +0.60, GoPro (GPRO) 1.09% +0.56, Astex Pharmaceuticals Inc (ASTX) 13.96% +0.54, Gold Miners ETF (GDX) 1.16% +0.52, Tidal Trust II (IRE) 24.90% +0.48, and Ventyx Biosciences (VTYX) 0.80% +0.46.
Oppenheimer Downgrades Ventyx Biosciences to Perform After Eli Lilly's $14 Acquisition
Oppenheimer analyst Jeff Jones downgraded Ventyx Biosciences to Perform from Outperform without a price target after after Eli Lilly entered an agreement to acquire all outstanding shares of Ventyx for $14 in cash.
Canaccord Downgrades Ventyx Biosciences to Hold, Price Target Cut to $14
Canaccord analyst Edward Nash downgraded Ventyx Biosciences to Hold from Buy with a price target of $14, down from $16, after the company entered into an agreement for Eli Lilly to acquire it at a price of $14 per share in an all-cash transaction. The firm believes the acquisition will not encounter any antitrust issues.
Clear Street Downgrades Ventyx Biosciences to Hold, Price Target Raised to $14
Clear Street analyst Kaveri Pohlman downgraded Ventyx Biosciences (VTYX) to Hold from Buy with a price target of $14, up from $11, after Eli Lilly (LLY) agreed to acquire Ventyx for $1.2B. Eli Lilly is a "logical" buyer given its focus on cardiometabolic health, immunology, and neuroscience, which aligns with Ventyx's programs, the analyst tells investors in a research note. The firm added that Lilly currently lacks NLRP3 assets, suggesting Ventyx's portfolio would complement its cardiometabolic and neurodegenerative franchises and could pair with existing therapies.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。